• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma-induced bone disease.

作者信息

Li Xin, Ling Wen, Barlogie Bart, Yaccoby Shmuel

机构信息

Department of Internal Medicine, Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University ofArkansas for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

Clin Transl Med. 2025 May;15(5):e70302. doi: 10.1002/ctm2.70302.

DOI:10.1002/ctm2.70302
PMID:40426299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12116329/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/082331a34a10/CTM2-15-e70302-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/b51e3febc3f9/CTM2-15-e70302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/596a3c29b59e/CTM2-15-e70302-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/008b6e643aa7/CTM2-15-e70302-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/082331a34a10/CTM2-15-e70302-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/b51e3febc3f9/CTM2-15-e70302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/596a3c29b59e/CTM2-15-e70302-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/008b6e643aa7/CTM2-15-e70302-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d6b/12116329/082331a34a10/CTM2-15-e70302-g003.jpg

相似文献

1
Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma-induced bone disease.间充质干细胞细胞疗法诱导HMOX1表达可抑制破骨细胞生成和骨髓瘤诱导的骨病。
Clin Transl Med. 2025 May;15(5):e70302. doi: 10.1002/ctm2.70302.
2
Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.骨内和全身间充质干细胞细胞治疗骨髓瘤骨病和肿瘤生长的疗效。
J Bone Miner Res. 2012 Aug;27(8):1635-48. doi: 10.1002/jbmr.1620.
3
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.人胎盘源贴壁细胞可防止骨质流失、刺激骨形成，并抑制骨髓瘤在骨内的生长。
Stem Cells. 2011 Feb;29(2):263-73. doi: 10.1002/stem.572.
4
pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.pIL6-TRAIL 工程化脐带间充质/基质干细胞在体外和体内对骨髓瘤细胞均具有高细胞毒性。
Stem Cell Res Ther. 2017 Sep 29;8(1):206. doi: 10.1186/s13287-017-0655-6.
5
Murine Bone Marrow Mesenchymal Stromal Cells Respond Efficiently to Oxidative Stress Despite the Low Level of Heme Oxygenases 1 and 2.尽管血红素加氧酶 1 和 2 的水平较低，鼠骨髓间充质基质细胞仍能有效地对氧化应激作出反应。
Antioxid Redox Signal. 2018 Jul 10;29(2):111-127. doi: 10.1089/ars.2017.7097. Epub 2018 Jan 3.
6
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.骨髓瘤细胞的接触会在骨骼前体细胞中诱导出一种特征性的转录组特征——对骨髓瘤骨病的影响。
Bone. 2016 Dec;93:155-166. doi: 10.1016/j.bone.2016.08.006. Epub 2016 Aug 9.
7
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.在骨髓瘤患者的骨祖细胞中，ephrinB2/EphB4轴失调，其激活会影响骨髓瘤骨病和肿瘤生长。
Blood. 2009 Aug 27;114(9):1803-12. doi: 10.1182/blood-2009-01-201954. Epub 2009 Jul 13.
8
Gender-independent efficacy of mesenchymal stem cell therapy in sex hormone-deficient bone loss via immunosuppression and resident stem cell recovery.间充质干细胞通过免疫抑制和驻留干细胞恢复治疗性激素缺乏性骨丢失的性别无关疗效。
Exp Mol Med. 2018 Dec 17;50(12):1-14. doi: 10.1038/s12276-018-0192-0.
9
Hmox1 promotes osteogenic differentiation at the expense of reduced adipogenic differentiation induced by BMP9 in C3H10T1/2 cells.Hmox1 通过降低 BMP9 诱导的 C3H10T1/2 细胞成脂分化来促进成骨分化。
J Cell Biochem. 2018 Jul;119(7):5503-5516. doi: 10.1002/jcb.26714. Epub 2018 Mar 25.
10
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.临床癌症细胞治疗中的间充质干细胞：系统评价。
Stem Cell Res Ther. 2018 Dec 7;9(1):336. doi: 10.1186/s13287-018-1078-8.

本文引用的文献

1
Essentiality of Nfatc1 short isoform in osteoclast differentiation and its self-regulation.NFATc1 短型异构体在破骨细胞分化中的必要性及其自我调控。
Sci Rep. 2023 Nov 1;13(1):18797. doi: 10.1038/s41598-023-45909-3.
2
Nuclear Factor-Kappa B Regulation of Osteoclastogenesis and Osteoblastogenesis.核因子-κB 对破骨细胞和骨细胞生成的调控。
Endocrinol Metab (Seoul). 2023 Oct;38(5):504-521. doi: 10.3803/EnM.2023.501. Epub 2023 Sep 26.
3
HO-1 in Bone Biology: Potential Therapeutic Strategies for Osteoporosis.骨生物学中的血红素加氧酶-1：骨质疏松症的潜在治疗策略
Front Cell Dev Biol. 2021 Nov 30;9:791585. doi: 10.3389/fcell.2021.791585. eCollection 2021.
4
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.新诊断多发性骨髓瘤患者的骨髓微环境与患者结局的相关性：总治疗临床试验中患者的队列研究。
PLoS Med. 2020 Nov 4;17(11):e1003323. doi: 10.1371/journal.pmed.1003323. eCollection 2020 Nov.
5
Curing myeloma at last: defining criteria and providing the evidence.最终治愈骨髓瘤：界定标准并提供证据。
Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.
6
Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.骨内和全身间充质干细胞细胞治疗骨髓瘤骨病和肿瘤生长的疗效。
J Bone Miner Res. 2012 Aug;27(8):1635-48. doi: 10.1002/jbmr.1620.
7
Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis.抑制 RANKL 依赖性血红素加氧酶-1 是高迁移率族蛋白 B1 释放和破骨细胞形成所必需的。
J Cell Biochem. 2012 Feb;113(2):486-98. doi: 10.1002/jcb.23372.
8
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.人胎盘源贴壁细胞可防止骨质流失、刺激骨形成，并抑制骨髓瘤在骨内的生长。
Stem Cells. 2011 Feb;29(2):263-73. doi: 10.1002/stem.572.
9
Advances in the understanding of myeloma bone disease and tumour growth.对骨髓瘤骨病和肿瘤生长的认识进展。
Br J Haematol. 2010 May;149(3):311-21. doi: 10.1111/j.1365-2141.2010.08141.x. Epub 2010 Mar 11.
10
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.超二倍体和非超二倍体人类骨髓瘤细胞系的建立与应用
Br J Haematol. 2007 Sep;138(6):802-11. doi: 10.1111/j.1365-2141.2007.06742.x.